Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

433.07
-20.6700-4.56%
Post-market: 433.300.2300+0.05%19:49 EDT
Volume:1.92M
Turnover:837.06M
Market Cap:109.88B
PE:28.27
High:452.00
Open:450.95
Low:431.01
Close:453.74
52wk High:510.77
52wk Low:362.50
Shares:253.72M
Float Shares:253.72M
Volume Ratio:1.38
T/O Rate:0.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):15.32
EPS(LYR):15.32
ROE:22.54%
ROA:12.16%
PB:5.89
PE(LYR):28.27

Loading ...

Vertex Pharmaceuticals price target raised to $585 from $575 at Citi

TIPRANKS
·
Mar 10

These Stocks Are Today's Movers: Occidental, Vertex, HPE, TSMC, Oracle, and More -- Barrons.com

Dow Jones
·
Mar 10

BUZZ-Street View: Vertex's kidney drug trial success boosts analysts' confidence

Reuters
·
Mar 10

Morgan Stanley Adjusts PT on Vertex Pharmaceuticals to $596 From $570, Maintains Overweight Rating

MT Newswires Live
·
Mar 10

Vertex Stock Jumps. What Wall Street Is Saying About Its Kidney Drug Trial. -- Barrons.com

Dow Jones
·
Mar 10

Vertex Pharmaceuticals: Upgraded Confidence in Povetacicept Drives Strengthened Buy Thesis After Robust Phase III RAINIER Data in IgA Nephropathy

TIPRANKS
·
Mar 10

Vertex Raises FY Dividend Plan to Y35.00

Dow Jones
·
Mar 10

Vertex Pharmaceuticals Inc : Oppenheimer Raises Target Price to $600 From $540

THOMSON REUTERS
·
Mar 10

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and HCA Healthcare (HCA)

TIPRANKS
·
Mar 10

Major Vertex Stakeholder Makes Notable Move With Fresh Stock Sale

TIPRANKS
·
Mar 10

Vertex Pharmaceuticals Shares Surge After-Hours as Kidney Drug Meets Late-Stage Trial Goals

Stock News
·
Mar 10

BRIEF-Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Reuters
·
Mar 10

Vertex Pharmaceuticals up 7% at $492 after positive Povetacicept results

TIPRANKS
·
Mar 10

Vertex Pharmaceuticals Stock Jumps After The Close: Here's Why

Benzinga_recent_news
·
Mar 10

Vertex Pharmaceuticals Shares up 6.75% at $492 in Extended Trade Following Trial Results for Kidney Disease Drug

THOMSON REUTERS
·
Mar 10

Vertex's kidney disease drug meets main goal in late-stage trial

Reuters
·
Mar 10

Vertex Pharmaceuticals announces positive week 36 results in Povetacicept study

TIPRANKS
·
Mar 10

Vertex Pharmaceuticals Inc - to Complete Bla for Povetacicept by End of March for Potential U.S. Accelerated Approval

THOMSON REUTERS
·
Mar 10

Vertex Pharmaceuticals: Povetacicept Was Generally Safe and Well Tolerated

THOMSON REUTERS
·
Mar 10

Absci names Ransi Somaratne chief medical officer as Andreas Busch set to retire

Reuters
·
Mar 07